

22 February 2022

ASX ANNOUNCEMENT

MVP FY22 HY Results and Investor Presentation

Medical Developments International Ltd (ASX: MVP) advises that on Thursday 24 August 2022 it will release its half year results for the 6 months ended 31 December 2021 (FY22 HY). Investors are invited to join a live investor presentation on Friday 25 February 2022 at 10am AEDT, provided by MVP Chair, Gordon Naylor and MVP CEO, Brent MacGregor.

Investors can register in advance for this presentation via the following link:

<https://us02web.zoom.us/meeting/register/tZMpceqpgTsvH9WuYm0evrIBU3ydUpIXsxhN>

After registering, you will receive a confirmation email containing information about joining the meeting.

MVP will upload a recording of the presentation to its website which will be accessible via the following link - <https://medicaldev.com/investors-media/>.

Authorised for release by MVP Company Secretary, Mark Edwards.

Enquiries:

Mark Edwards
Company Secretary
+61 (3) 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.